CN111343981A - 使用川地匹坦治疗胃肠疾病的方法 - Google Patents

使用川地匹坦治疗胃肠疾病的方法 Download PDF

Info

Publication number
CN111343981A
CN111343981A CN201880073477.9A CN201880073477A CN111343981A CN 111343981 A CN111343981 A CN 111343981A CN 201880073477 A CN201880073477 A CN 201880073477A CN 111343981 A CN111343981 A CN 111343981A
Authority
CN
China
Prior art keywords
trandipitant
gastroparesis
disease
responsive
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073477.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·H·波利梅洛伯罗斯
G·比尔茨尼克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Priority to CN202411421827.XA priority Critical patent/CN119074729A/zh
Publication of CN111343981A publication Critical patent/CN111343981A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880073477.9A 2017-11-17 2018-11-16 使用川地匹坦治疗胃肠疾病的方法 Pending CN111343981A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411421827.XA CN119074729A (zh) 2017-11-17 2018-11-16 使用川地匹坦治疗胃肠疾病的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
US62/587,681 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411421827.XA Division CN119074729A (zh) 2017-11-17 2018-11-16 使用川地匹坦治疗胃肠疾病的方法

Publications (1)

Publication Number Publication Date
CN111343981A true CN111343981A (zh) 2020-06-26

Family

ID=64734107

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880073477.9A Pending CN111343981A (zh) 2017-11-17 2018-11-16 使用川地匹坦治疗胃肠疾病的方法
CN202411421827.XA Pending CN119074729A (zh) 2017-11-17 2018-11-16 使用川地匹坦治疗胃肠疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411421827.XA Pending CN119074729A (zh) 2017-11-17 2018-11-16 使用川地匹坦治疗胃肠疾病的方法

Country Status (19)

Country Link
US (4) US20200030307A1 (https=)
EP (1) EP3710000B1 (https=)
JP (1) JP7306614B2 (https=)
KR (2) KR20250140655A (https=)
CN (2) CN111343981A (https=)
AU (1) AU2018367623B2 (https=)
BR (1) BR112020009520A2 (https=)
CA (1) CA3081582A1 (https=)
CL (1) CL2020001290A1 (https=)
DK (1) DK3710000T3 (https=)
ES (1) ES3032138T3 (https=)
FI (1) FI3710000T3 (https=)
HR (1) HRP20250615T1 (https=)
HU (1) HUE071527T2 (https=)
IL (1) IL274541B2 (https=)
MX (1) MX2020005167A (https=)
PT (1) PT3710000T (https=)
SI (1) SI3710000T1 (https=)
WO (1) WO2019099883A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978736C (en) * 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
KR102863233B1 (ko) * 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863791A (zh) * 2003-10-24 2006-11-15 伊莱利利公司 {2－[1－(3,5－双－三氟甲基－苄基)－5－吡啶－4－基－1h－[1,2,3]三唑－4－基]－吡啶－3－基}－(2－氯苯基)－甲酮的新晶形
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
CN102655864A (zh) * 2009-11-18 2012-09-05 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100755577B1 (ko) 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체
WO2017112792A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863791A (zh) * 2003-10-24 2006-11-15 伊莱利利公司 {2－[1－(3,5－双－三氟甲基－苄基)－5－吡啶－4－基－1h－[1,2,3]三唑－4－基]－吡啶－3－基}－(2－氯苯基)－甲酮的新晶形
US20070078166A1 (en) * 2003-10-24 2007-04-05 Eli Lilly And Company Patent Division Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3] triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
CN102655864A (zh) * 2009-11-18 2012-09-05 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACOB D, ET AL.: "Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant", 《AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY》 *
PASRICHA P J,ET AL.: "Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders", 《GASTROENTEROLOGY》 *

Also Published As

Publication number Publication date
SI3710000T1 (sl) 2025-07-31
CL2020001290A1 (es) 2020-11-13
KR20200088346A (ko) 2020-07-22
IL274541A (en) 2020-06-30
IL274541B1 (en) 2024-06-01
WO2019099883A1 (en) 2019-05-23
NZ764107A (en) 2024-07-05
AU2018367623A1 (en) 2020-05-21
MX2020005167A (es) 2020-08-20
KR20250140655A (ko) 2025-09-25
EP3710000A1 (en) 2020-09-23
IL274541B2 (en) 2024-10-01
ES3032138T3 (en) 2025-07-15
JP2021503480A (ja) 2021-02-12
PT3710000T (pt) 2025-05-29
KR102864285B1 (ko) 2025-09-24
CA3081582A1 (en) 2019-05-23
US20230390269A1 (en) 2023-12-07
US20210093621A1 (en) 2021-04-01
US20210330656A1 (en) 2021-10-28
JP7306614B2 (ja) 2023-07-11
DK3710000T3 (da) 2025-06-16
EP3710000B1 (en) 2025-04-23
BR112020009520A2 (pt) 2020-11-03
CN119074729A (zh) 2024-12-06
FI3710000T3 (fi) 2025-07-03
HRP20250615T1 (hr) 2025-07-18
HUE071527T2 (hu) 2025-09-28
AU2018367623B2 (en) 2024-03-28
RU2020119259A (ru) 2021-12-17
US20200030307A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US20230390269A1 (en) Method of treatment with tradipitant
US20220096449A1 (en) Method of treatment with tradipitant
US20240285588A1 (en) Use of tradipitant in motion sickness
Kobayashi et al. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo
US20210008037A1 (en) Use of tradipitant in motion sickness
Amaral et al. Targeting the NMDA receptor for fear-related disorders
Yaoita et al. Involvement of peripheral alpha2A adrenoceptor in the acceleration of gastrointestinal transit and abdominal visceral pain induced by intermittent deprivation of REM sleep
RU2797248C2 (ru) Способ лечения заболеваний желудочно-кишечного тракта традипитантом
US20240299373A1 (en) Improved use of tradipitant in motion sickness
RU2808669C2 (ru) Применение традипитанта от укачивания
NZ766397B2 (en) Use of tradipitant in motion sickness

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination